Yanfeng Liu
Research Associate 2, MSCards
About
Research
Publications
2025
PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7
Colón-Ríos D, Dow J, Krysztofiak A, Liu Y, Rogers F, Glazer P. PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. NAR Cancer 2025, 7: zcaf047. PMID: 41357766, PMCID: PMC12675010, DOI: 10.1093/narcan/zcaf047.Peer-Reviewed Original ResearchThis study investigates how IDH1-mutant cancers develop resistance to PARP inhibitors through loss of end protection factors, 53BP1 and REV7, and shows that the drug cediranib can overcome this resistance, highlighting potential therapeutic strategies for improving cancer treatment outcomes.Cell-penetrating antibody enhances nuclear delivery of triplex-forming oligonucleotides targeting HER2-positive cancers
Minnah A, Tubéns N, Krysztofiak A, Liu Y, Glazer P, Rogers F. Cell-penetrating antibody enhances nuclear delivery of triplex-forming oligonucleotides targeting HER2-positive cancers. Molecular Therapy - Nucleic Acids 2025, 36: 102720. PMID: 41127334, PMCID: PMC12538099, DOI: 10.1016/j.omtn.2025.102720.Peer-Reviewed Original ResearchNucleic acid therapiesNuclear deliveryBreast cancer modelHER2-positive cancersTriplex-forming oligonucleotidesCancer treatment optionsTumor-targeting propertiesPrecision cancer therapyAnti-DNA monoclonal antibodyTreatment optionsCancer modelsCell-penetrating antibodiesBinding extracellular DNACancer therapyClinical translationMonoclonal antibodiesDelivery efficiencyIn vitroNecrotic regionsTherapyExtracellular DNADelivery systemAntibodiesDeliveryHER2Hypoxia Induces Immunosuppression by Silencing STING in Cancer.
Lu Y, Yurkevicz A, Liu Y, Glazer P. Hypoxia Induces Immunosuppression by Silencing STING in Cancer. Cancer Research 2025, 85: 4664-4680. PMID: 40939188, PMCID: PMC12498107, DOI: 10.1158/0008-5472.can-24-2038.Peer-Reviewed Original ResearchThis study shows that tumor hypoxia silences the STING pathway, impairing immune response in cancer, and suggests targeting KDM1A to restore STING and enhance cancer therapy.
2024
Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate.
Yurkevicz A, Liu Y, Katz S, Glazer P. Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate. Molecular Cancer Therapeutics 2024, 24: 105-117. PMID: 39382073, PMCID: PMC11695185, DOI: 10.1158/1535-7163.mct-23-0809.Peer-Reviewed Original ResearchMajor histocompatibility complexT cellsTumor cellsTreatment of tumor-bearing miceMajor histocompatibility complex class I pathwaySuppression of tumor growthTumor cells in vivoT-cell therapySyngeneic tumor modelsTumor-specific antigensTumor-bearing miceMelanoma tumor cellsT cell activationHealthy tissueTarget tumor cellsIn vivoIn vitroMicroenvironment of tumorsUnique delivery platformsClass I pathwayCell-based therapiesTargeted cancer therapyCells in vivoAntigen processing pathwayAcidic microenvironment of tumorsNext-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition
Rackear M, Quijano E, Ianniello Z, Colón-Ríos D, Krysztofiak A, Abdullah R, Liu Y, Rogers F, Ludwig D, Dwivedi R, Bleichert F, Glazer P. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget 2024, 15: 699-713. PMID: 39352803, PMCID: PMC11444335, DOI: 10.18632/oncotarget.28651.Peer-Reviewed Original ResearchConceptsTumor targetingMonoclonal antibody therapyTumor-specific targetingCell uptakeNucleic acid bindingCell surface antigensAntibody therapyHuman variantsClinical successCell-penetrating antibodiesAcid bindingSystemic administrationSurface antigensTumorRAD51 inhibitionAntibody platformMechanism of cell penetrationBind RAD51AntibodiesFull-lengthSpecific targetsCell penetrationDisease targetsCellsAutoantibodies
Academic Achievements & Community Involvement
News
Get In Touch
Contacts
Email